RaQualia Pharma Inc. (4579.T)
JPY 337.0
(0.9%)
JPY 337.0
(0.9%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -111.8 Million JPY | -115.33% |
| 2022 | 1 Billion JPY | 3.76% |
| 2021 | 1.02 Billion JPY | 351.87% |
| 2020 | -403.24 Million JPY | -453.54% |
| 2019 | 124 Million JPY | 112.21% |
| 2018 | -950 Million JPY | -1019.77% |
| 2017 | -65 Million JPY | 87.82% |
| 2016 | -679.99 Million JPY | 60.48% |
| 2015 | -1.81 Billion JPY | 17.43% |
| 2014 | -2.16 Billion JPY | 24.57% |
| 2013 | -2.07 Billion JPY | -7.28% |
| 2012 | -2.6 Billion JPY | -36.94% |
| 2011 | -1.89 Billion JPY | -43.54% |
| 2010 | -1.32 Billion JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 89.65 Million JPY | 156.51% |
| 2024 Q2 | -152.3 Million JPY | -175.27% |
| 2023 Q4 | -174.23 Million JPY | -1369.83% |
| 2023 FY | - JPY | -115.33% |
| 2023 Q1 | -74.23 Million JPY | -129.1% |
| 2023 Q2 | 218.26 Million JPY | 394.02% |
| 2023 Q3 | -11.85 Million JPY | -105.43% |
| 2022 Q1 | -21.19 Million JPY | -103.2% |
| 2022 FY | - JPY | 3.76% |
| 2022 Q4 | 255.06 Million JPY | 37664.8% |
| 2022 Q3 | -679 Thousand JPY | -100.08% |
| 2022 Q2 | 822.02 Million JPY | 3978.73% |
| 2021 Q1 | 303.1 Million JPY | 161.54% |
| 2021 Q2 | 199.11 Million JPY | -34.31% |
| 2021 Q4 | 662.31 Million JPY | 548.9% |
| 2021 Q3 | -147.54 Million JPY | -174.1% |
| 2021 FY | - JPY | 351.87% |
| 2020 Q3 | -158.96 Million JPY | -57.53% |
| 2020 FY | - JPY | -453.54% |
| 2020 Q2 | -100.9 Million JPY | 61.16% |
| 2020 Q1 | -259.79 Million JPY | -146.55% |
| 2020 Q4 | 115.89 Million JPY | 172.91% |
| 2019 FY | - JPY | 112.21% |
| 2019 Q3 | -199.47 Million JPY | -15.93% |
| 2019 Q4 | 558.11 Million JPY | 379.8% |
| 2019 Q1 | -72.37 Million JPY | 63.31% |
| 2019 Q2 | -172.06 Million JPY | -137.75% |
| 2018 FY | - JPY | -1019.77% |
| 2018 Q4 | -197.26 Million JPY | 20.05% |
| 2018 Q1 | -203.28 Million JPY | -147.38% |
| 2018 Q2 | -288.18 Million JPY | -41.77% |
| 2018 Q3 | -246.73 Million JPY | 14.38% |
| 2017 Q1 | -46.06 Million JPY | 82.23% |
| 2017 FY | - JPY | 87.82% |
| 2017 Q4 | 429.09 Million JPY | 326.5% |
| 2017 Q3 | -189.44 Million JPY | 31.64% |
| 2017 Q2 | -277.11 Million JPY | -501.54% |
| 2016 Q2 | -278.76 Million JPY | -312.55% |
| 2016 FY | - JPY | 60.48% |
| 2016 Q1 | 131.15 Million JPY | 144.9% |
| 2016 Q3 | -279.24 Million JPY | -0.17% |
| 2016 Q4 | -259.21 Million JPY | 7.17% |
| 2015 Q3 | -550.09 Million JPY | -31.16% |
| 2015 FY | - JPY | 17.43% |
| 2015 Q1 | -474.5 Million JPY | -154.6% |
| 2015 Q2 | -419.42 Million JPY | 11.61% |
| 2015 Q4 | -292.12 Million JPY | 46.9% |
| 2014 FY | - JPY | 24.57% |
| 2014 Q4 | 869.07 Million JPY | 291.31% |
| 2014 Q3 | -454.27 Million JPY | -0.13% |
| 2014 Q2 | -453.69 Million JPY | 78.02% |
| 2014 Q1 | -2.06 Billion JPY | -73.05% |
| 2013 Q1 | -525.93 Million JPY | 18.14% |
| 2013 Q4 | -1.19 Billion JPY | -136.46% |
| 2013 Q3 | -504.33 Million JPY | 10.66% |
| 2013 Q2 | -564.53 Million JPY | -7.34% |
| 2013 FY | - JPY | -7.28% |
| 2012 Q3 | -647.6 Million JPY | 2.65% |
| 2012 Q1 | -653.24 Million JPY | -7.26% |
| 2012 FY | - JPY | -36.94% |
| 2012 Q4 | -642.47 Million JPY | 0.79% |
| 2012 Q2 | -665.24 Million JPY | -1.84% |
| 2011 Q3 | -727.19 Million JPY | -25.5% |
| 2011 FY | - JPY | -43.54% |
| 2011 Q4 | -609.02 Million JPY | 16.25% |
| 2011 Q1 | 18.31 Million JPY | 0.0% |
| 2011 Q2 | -579.44 Million JPY | -3264.1% |
| 2010 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 958.1 Million JPY | 111.669% |
| PRISM BioLab Co.,LTD | -488.13 Million JPY | 77.096% |
| GNI Group Ltd. | 14.48 Billion JPY | 100.772% |
| Linical Co., Ltd. | 1.24 Billion JPY | 108.964% |
| Trans Genic Inc. | 240.95 Million JPY | 146.4% |
| MEDINET Co., Ltd. | -1.35 Billion JPY | 91.754% |
| Soiken Holdings Inc. | -583.2 Million JPY | 80.83% |
| Cytori Cell Research Institute, Inc. | -603.09 Million JPY | 81.462% |
| AnGes, Inc. | -8.86 Billion JPY | 98.738% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | 91.303% |
| Nxera Pharma Co., Ltd. | -7.39 Billion JPY | 98.489% |
| Immuno-Biological Laboratories Co., Ltd. | 128.1 Million JPY | 187.272% |
| NanoCarrier Co., Ltd. | -863 Million JPY | 87.045% |
| Carna Biosciences, Inc. | -1.09 Billion JPY | 89.76% |
| CanBas Co., Ltd. | 53.65 Million JPY | 308.386% |
| D. Western Therapeutics Institute, Inc. | -775.59 Million JPY | 85.585% |
| Chiome Bioscience Inc. | -1.21 Billion JPY | 90.773% |
| Kidswell Bio Corporation | -1.38 Billion JPY | 91.903% |
| PeptiDream Inc. | 7.37 Billion JPY | 101.516% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 94.206% |
| Ribomic Inc. | -1.01 Billion JPY | 88.958% |
| SanBio Company Limited | -4.52 Billion JPY | 97.529% |
| Healios K.K. | -3 Billion JPY | 96.282% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | 90.41% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 91.974% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 92.026% |
| StemRIM | -2.03 Billion JPY | 94.498% |
| CellSource Co., Ltd. | 1.3 Billion JPY | 108.558% |
| FunPep Company Limited | -952 Million JPY | 88.256% |
| Kringle Pharma, Inc. | -888.76 Million JPY | 87.421% |
| Stella Pharma Corporation | -723.85 Million JPY | 84.555% |
| TMS Co., Ltd. | -937 Million JPY | 88.068% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | 85.581% |
| Cuorips Inc. | -518 Million JPY | 78.417% |
| K Pharma,Inc. | 366.05 Million JPY | 130.542% |
| Takara Bio Inc. | 8.02 Billion JPY | 101.393% |
| ReproCELL Incorporated | 8.24 Million JPY | 1455.985% |
| PhoenixBio Co., Ltd. | 87.93 Million JPY | 227.136% |
| StemCell Institute Inc. | 534.35 Million JPY | 120.923% |
| Japan Tissue Engineering Co., Ltd. | 244.81 Million JPY | 145.668% |
| CellSeed Inc. | -836.51 Million JPY | 86.635% |